Date: 2012-10-23
Type of information: R&D agreement
Compound: small molecules targeting G-Protein Coupled Receptors (GPCRs) selected by Ono
Company: Domain Therapeutics (France) Ono Pharmaceutical (Japan)
Therapeutic area: undisclosed
Type agreement: R&D
Action mechanism:
Disease: undisclosed
Details: Domain Therapeutics and Ono Pharmaceutical have signed a collaboration agreement focused on discovering small molecules targeting G-Protein Coupled Receptors (GPCRs). Under the agreement, Ono will provide Domain Therapeutics with an upfront payment, pay research funding for the collaborative research programs and success-based milestones on the research and development progress, as well as royalties on sales of the products. Domain Therapeutics will apply DTect-All™, its proprietary GPCR drug discovery platform, and its expertise in GPCR medicinal chemistry and pharmacology to design and optimize small molecules into drug candidates having activity against GPCRs selected by Ono. Ono will have worldwide exclusive rights to develop and commercialize any pharmaceutical product arising out of the drug discovery collaboration.
Financial terms:
Latest news:
